Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. (not Eyepoint, Inc.) on September 28, 2016, reporting events occurring on September 26, 2016. The registrant is a Delaware corporation headquartered in Watertown, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Board Expansion: The Board of Directors increased its size to six members.
- Director Appointment: Jay S. Duker was appointed as a director and member of the Science Committee.
- Compensatory Arrangement: Dr. Duker received an initial grant of options to purchase 40,000 shares of common stock, vesting in three equal installments over three years, subject to shareholder approval.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. No specific risks or contingencies were disclosed in this report, other than the standard requirement for shareholder approval regarding the stock option grant.
Investor Verification Checklist
- Verify the correct registrant name is pSivida Corp., not Eyepoint, Inc.
- Confirm the status of shareholder approval for Dr. Duker's 40,000 share option grant.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Check for any related party transactions involving Dr. Duker's other directorships (Eleven Biotherapeutics, Hemera Biosciences).